| # | Drug | Count |
|---|---|---|
| 0 | RITUXIMAB | 586 |
| 1 | CYCLOPHOSPHAMIDE | 542 |
| 2 | DOXORUBICIN | 493 |
| 3 | PREDNISONE | 414 |
| 4 | DEXAMETHASONE | 232 |
| 5 | DEXAMETHASONE 1.5 MG | 232 |
| 6 | ETOPOSIDE | 226 |
| 7 | CYTARABINE | 190 |
| 8 | DOXORUBICIN HYDROCHLORIDE | 179 |
| 9 | GEMCITABINE HYDROCHLORIDE | 175 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | POLATUZUMAB VEDOTIN | 107 | 0.0601 |
| 1 | WHITE PETROLEUM | 1 | 0.0167 |
| 2 | BRINCIDOFOVIR | 1 | 0.0127 |
| 3 | IFOSFAMIDE | 137 | 0.0104 |
| 4 | DOXORUBICIN | 493 | 0.0094 |
| 5 | VINCRISTINE SULFATE | 132 | 0.0065 |
| 6 | DOXORUBICIN HYDROCHLORIDE | 179 | 0.0063 |
| 7 | ETOPOSIDE PHOSPHATE | 6 | 0.0059 |
| 8 | GEMCITABINE HYDROCHLORIDE | 175 | 0.0055 |
| 9 | CYCLOPHOSPHAMIDE | 542 | 0.0051 |
| # | Drug class | Count |
|---|---|---|
| 0 | Corticosteroid [EPC] | 644 |
| 1 | CD20-directed Cytolytic Antibody [EPC] | 595 |
| 2 | Alkylating Drug [EPC] | 578 |
| 3 | Nucleoside Metabolic Inhibitor [EPC] | 306 |
| 4 | Platinum-based Drug [EPC] | 306 |
| 5 | Topoisomerase Inhibitor [EPC] | 226 |
| 6 | Folate Analog Metabolic Inhibitor [EPC] | 136 |
| 7 | Thalidomide Analog [EPC] | 71 |
| 8 | Nonsteroidal Anti-inflammatory Drug [EPC] | 45 |
| 9 | Platelet Aggregation Inhibitor [EPC] | 45 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Topoisomerase Inhibitor [EPC] | 226 | 0.0048 |
| 1 | Alkylating Drug [EPC] | 578 | 0.0034 |
| 2 | CD20-directed Cytolytic Antibody [EPC] | 595 | 0.0033 |
| 3 | Platinum-based Drug [EPC] | 306 | 0.0019 |
| 4 | Echinocandin Antifungal [EPC] | 7 | 0.0015 |
| 5 | Nucleoside Metabolic Inhibitor [EPC] | 306 | 0.0015 |
| 6 | Hematopoietic Stem Cell Mobilizer [EPC] | 1 | 0.0009 |
| 7 | Corticosteroid [EPC] | 644 | 0.0007 |
| 8 | Antimalarial [EPC] | 4 | 0.0007 |
| 9 | 5-alpha Reductase Inhibitor [EPC] | 34 | 0.0006 |